Malignant Thymus Neoplasm — Trials

Malignant Thymus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

193 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 80
Recruiting: 43
Ph III recruiting: 1
Growth YoY: —
Industry share: 23%
Top sponsor: Jonsson Comprehensive Cancer Center
Termination share: 30.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02623920	Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma(S-BR)	withdrawn	Phase 2	0	University of ArizonaOTHER	1	May 19, 2017	clinicaltrials
NCT02653989	Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)	withdrawn	Phase 2	0	Medivation, Inc.INDUSTRY	1	Nov 25, 2016